FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2557635055> ?p ?o ?g. }

• W2557635055 endingPage "4183" @default.
• W2557635055 startingPage "4183" @default.
• W2557635055 abstract "Abstract INTRODUCTION: Patients who receive non-renal solid organ transplants have a reported 4-30% incidence of post transplant thrombotic microangiopathy (PT-TMA). The development of PT- TMA is associated with a significant increase in early mortality when compared to patients with no PT-TMA. Mortality rates as high as 70% are associated with PT-TMA in spite of plasma exchange therapy. The factors which contribute to this high mortality are poorly understood. New findings suggest that this form of TMA is complement mediated and can be classified as PT-aHUS. We and others have reported the clinical and laboratory benefits of treating PT-aHUS with eculizumab. There are suggestions of a link between PT-TMA and decreased graft survival although the mechanism is not well understood. Theories include: 1) chronic ischemia from TMA, 2) chronic/low grade antibody mediated rejection (perhaps contributed to by alloimmunization from transfusions) and 3) direct damage to graft mediated by complement. The role that multiple post transplant transfusions plays in poor overall and/or poor graft survival in these patients has not been evaluated, but is intriguing. MATERIALS and METHODS: We report our experience with 9 patients who underwent non renal solid organ transplantation (7 small bowel and 2 orthotopic liver) in 2011 - 2013 at our institution who were diagnosed clinically with PT-aHUS and treated with eculizumab. Blood component use was evaluated from the date of transplant (DOT) to the date of initiation of eculizumab therapy 1-53 months (mean: 11 months) and after initiation of eculizumab therapy 6-24 months (mean: 13 months). Criteria for transfusions and the clinical team were unchanged during the study period. RESULTS: Red blood cell (RBC) transfusions from the DOT to the date of eculizumab initiation 5-53 units (mean: 31 units), PRBC transfusions post initiation of eculizumab therapy 0-41 units (mean: 11 units). Apheresis platelet (PLT) transfusions from the DOT to the date of eculizumab initiation 0-7 units (mean: 3 units), PLT transfusions post initiation of eculizumab therapy 0-16 units (mean: 2units). Fresh frozen plasma (FFP) infusions from the DOT to the date of eulizumab initiation 0-272 units (mean: 43 units) FFP infusions post initiation of eculizumab therapy 1-10 units (mean: 2units). CONCLUSIONS: The significant reduction in RBC transfusions after the initiation of eculizumab demonstrates a previously unreported clinical benefit of the complement inhibitory effects of eculizumab in patients with PT-aHUS. While long term results remain to be determined continued monitoring of both overall patient and graft survival in these patients will be interesting. We hypothesize that early treatment of PT-aHUS with eculizumab minimizing the need for transfusion therapy will have a beneficial effect on overall patient as well as graft survival. Disclosures Broome: Alexion Pharmaceuticals: Honoraria." @default.
• W2557635055 created "2016-12-08" @default.
• W2557635055 creator A5031024904 @default.
• W2557635055 creator A5032702300 @default.
• W2557635055 creator A5051185612 @default.
• W2557635055 date "2014-12-06" @default.
• W2557635055 modified "2023-09-27" @default.
• W2557635055 title "Eculizumab Reduces Red Blood Cell Transfusions in Non-Renal Solid Organ Transplant Patients Diagnosed with Post Transplant Atypical Hemolytic Uremic Syndrome (PT-aHUS)" @default.
• W2557635055 doi "https://doi.org/10.1182/blood.v124.21.4183.4183" @default.
• W2557635055 hasPublicationYear "2014" @default.
• W2557635055 type Work @default.
• W2557635055 sameAs 2557635055 @default.
• W2557635055 citedByCount "0" @default.
• W2557635055 crossrefType "journal-article" @default.
• W2557635055 hasAuthorship W2557635055A5031024904 @default.
• W2557635055 hasAuthorship W2557635055A5032702300 @default.
• W2557635055 hasAuthorship W2557635055A5051185612 @default.
• W2557635055 hasConcept C111684460 @default.
• W2557635055 hasConcept C126322002 @default.
• W2557635055 hasConcept C141071460 @default.
• W2557635055 hasConcept C159654299 @default.
• W2557635055 hasConcept C203014093 @default.
• W2557635055 hasConcept C2777637130 @default.
• W2557635055 hasConcept C2777878052 @default.
• W2557635055 hasConcept C2777991916 @default.
• W2557635055 hasConcept C2779134260 @default.
• W2557635055 hasConcept C2911091166 @default.
• W2557635055 hasConcept C71924100 @default.
• W2557635055 hasConcept C90924648 @default.
• W2557635055 hasConceptScore W2557635055C111684460 @default.
• W2557635055 hasConceptScore W2557635055C126322002 @default.
• W2557635055 hasConceptScore W2557635055C141071460 @default.
• W2557635055 hasConceptScore W2557635055C159654299 @default.
• W2557635055 hasConceptScore W2557635055C203014093 @default.
• W2557635055 hasConceptScore W2557635055C2777637130 @default.
• W2557635055 hasConceptScore W2557635055C2777878052 @default.
• W2557635055 hasConceptScore W2557635055C2777991916 @default.
• W2557635055 hasConceptScore W2557635055C2779134260 @default.
• W2557635055 hasConceptScore W2557635055C2911091166 @default.
• W2557635055 hasConceptScore W2557635055C71924100 @default.
• W2557635055 hasConceptScore W2557635055C90924648 @default.
• W2557635055 hasIssue "21" @default.
• W2557635055 hasLocation W25576350551 @default.
• W2557635055 hasOpenAccess W2557635055 @default.
• W2557635055 hasPrimaryLocation W25576350551 @default.
• W2557635055 hasRelatedWork W2024870615 @default.
• W2557635055 hasRelatedWork W2034286783 @default.
• W2557635055 hasRelatedWork W2077986770 @default.
• W2557635055 hasRelatedWork W2128719952 @default.
• W2557635055 hasRelatedWork W2140370443 @default.
• W2557635055 hasRelatedWork W2141534367 @default.
• W2557635055 hasRelatedWork W2897797027 @default.
• W2557635055 hasRelatedWork W2904881915 @default.
• W2557635055 hasRelatedWork W2972154622 @default.
• W2557635055 hasRelatedWork W2997675070 @default.
• W2557635055 hasVolume "124" @default.
• W2557635055 isParatext "false" @default.
• W2557635055 isRetracted "false" @default.
• W2557635055 magId "2557635055" @default.
• W2557635055 workType "article" @default.